• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

存在特定病因风险时的生存外推法。

Survival extrapolation in the presence of cause specific hazards.

作者信息

Benaglia Tatiana, Jackson Christopher H, Sharples Linda D

机构信息

Department of Statistics, Universidade Estadual de Campinas, Sao Paulo, Brazil.

出版信息

Stat Med. 2015 Feb 28;34(5):796-811. doi: 10.1002/sim.6375. Epub 2014 Nov 20.

DOI:10.1002/sim.6375
PMID:25413028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4847642/
Abstract

Health economic evaluations require estimates of expected survival from patients receiving different interventions, often over a lifetime. However, data on the patients of interest are typically only available for a much shorter follow-up time, from randomised trials or cohorts. Previous work showed how to use general population mortality to improve extrapolations of the short-term data, assuming a constant additive or multiplicative effect on the hazards for all-cause mortality for study patients relative to the general population. A more plausible assumption may be a constant effect on the hazard for the specific cause of death targeted by the treatments. To address this problem, we use independent parametric survival models for cause-specific mortality among the general population. Because causes of death are unobserved for the patients of interest, a polyhazard model is used to express their all-cause mortality as a sum of latent cause-specific hazards. Assuming proportional cause-specific hazards between the general and study populations then allows us to extrapolate mortality of the patients of interest to the long term. A Bayesian framework is used to jointly model all sources of data. By simulation, we show that ignoring cause-specific hazards leads to biased estimates of mean survival when the proportion of deaths due to the cause of interest changes through time. The methods are applied to an evaluation of implantable cardioverter defibrillators for the prevention of sudden cardiac death among patients with cardiac arrhythmia. After accounting for cause-specific mortality, substantial differences are seen in estimates of life years gained from implantable cardioverter defibrillators.

摘要

卫生经济评估需要估计接受不同干预措施的患者的预期生存期,通常是终生的生存期。然而,感兴趣的患者的数据通常仅在较短的随访期内可得,这些数据来自随机试验或队列研究。先前的研究表明了如何利用一般人群死亡率来改进短期数据的外推,假设相对于一般人群,研究患者的全因死亡率的风险具有恒定的相加或相乘效应。一个更合理的假设可能是对治疗所针对的特定死因的风险具有恒定效应。为了解决这个问题,我们对一般人群中特定死因的死亡率使用独立的参数生存模型。由于感兴趣的患者的死亡原因是未观察到的,因此使用多风险模型将他们的全因死亡率表示为潜在的特定死因风险之和。假设一般人群和研究人群之间特定死因风险成比例,那么我们就可以将感兴趣的患者的死亡率外推到长期。使用贝叶斯框架对所有数据来源进行联合建模。通过模拟,我们表明,当因感兴趣的原因导致的死亡比例随时间变化时,忽略特定死因风险会导致平均生存期的估计出现偏差。这些方法被应用于一项关于植入式心脏复律除颤器预防心律失常患者心脏性猝死的评估。在考虑特定死因死亡率后,从植入式心脏复律除颤器获得的生命年估计值出现了显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/89da5c585be0/SIM-34-796-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/281dd5e1d372/SIM-34-796-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/c72552507a14/SIM-34-796-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/a7c591cd0830/SIM-34-796-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/2c163c1da9a0/SIM-34-796-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/ddc398bb8038/SIM-34-796-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/89da5c585be0/SIM-34-796-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/281dd5e1d372/SIM-34-796-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/c72552507a14/SIM-34-796-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/a7c591cd0830/SIM-34-796-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/2c163c1da9a0/SIM-34-796-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/ddc398bb8038/SIM-34-796-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cacd/6680213/89da5c585be0/SIM-34-796-g006.jpg

相似文献

1
Survival extrapolation in the presence of cause specific hazards.存在特定病因风险时的生存外推法。
Stat Med. 2015 Feb 28;34(5):796-811. doi: 10.1002/sim.6375. Epub 2014 Nov 20.
2
A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.对不同患者群体中植入式心脏复律除颤器治疗的效果和成本相关证据的综述,以及在英国背景下对这些群体的成本效益和成本效用进行建模。
Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. doi: 10.3310/hta10270.
3
Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.用于治疗心律失常的植入式心脏复律除颤器和用于治疗心力衰竭的心脏再同步治疗:系统评价与经济学评估
Health Technol Assess. 2014 Aug;18(56):1-560. doi: 10.3310/hta18560.
4
Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.适当的植入式心脏复律除颤器治疗在二级预防患者中的死亡率影响:前瞻性基于人群的登记处中一级预防患者死亡率的对比。
J Am Heart Assoc. 2017 Aug 19;6(8):e006220. doi: 10.1161/JAHA.117.006220.
5
Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.用于非缺血性心肌病患者的植入式心脏除颤器。
Cochrane Database Syst Rev. 2018 Dec 8;12(12):CD012738. doi: 10.1002/14651858.CD012738.pub2.
6
Impact of Chronic Total Coronary Occlusion on Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention Implantable Cardioverter-Defibrillator Recipients (VACTO Secondary Study): Insights From Coronary Angiogram and Electrogram Analysis.慢性完全性冠状动脉闭塞对缺血性二级预防植入式心脏复律除颤器受者室性心律失常复发的影响(VACTO 二级研究):来自冠状动脉造影和电图分析的见解。
JACC Cardiovasc Interv. 2017 May 8;10(9):879-888. doi: 10.1016/j.jcin.2017.02.008.
7
Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis.由于起搏诱导性心肌病而升级为心脏再同步治疗的患者发生危及生命的室性心律失常的风险较低:一项长期死因分析。
Europace. 2018 Jan 1;20(1):89-96. doi: 10.1093/europace/euw321.
8
Cost-effectiveness of implantable cardioverter-defibrillators.植入式心脏复律除颤器的成本效益
N Engl J Med. 2005 Oct 6;353(14):1471-80. doi: 10.1056/NEJMsa051989.
9
Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation.植入式心脏复律除颤器对接受心脏移植评估患者的猝死及总死亡率的影响。
Circulation. 1995 Dec 1;92(11):3273-81. doi: 10.1161/01.cir.92.11.3273.
10
Implantable cardioverter-defibrillators for secondary prevention: is it worth it in the elderly?用于二级预防的植入式心脏复律除颤器:对老年人来说值得吗?
Am J Geriatr Cardiol. 2006 Mar-Apr;15(2):93-9; quiz 100-1. doi: 10.1111/j.1076-7460.2006.04816.x.

引用本文的文献

1
survextrap: a package for flexible and transparent survival extrapolation.survextrap:一个用于灵活透明生存外推的软件包。
BMC Med Res Methodol. 2023 Nov 29;23(1):282. doi: 10.1186/s12874-023-02094-1.
2
Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.利用超额风险和治愈模型纳入一般人群死亡率的生存外推:教程。
Med Decis Making. 2023 Aug;43(6):737-748. doi: 10.1177/0272989X231184247. Epub 2023 Jul 13.
3
A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology Assessment.

本文引用的文献

1
Survival models in health economic evaluations: balancing fit and parsimony to improve prediction.健康经济评估中的生存模型:平衡拟合优度与简约性以改善预测
Int J Biostat. 2010;6(1):Article 34. doi: 10.2202/1557-4679.1269.
2
Survival extrapolation using the poly-Weibull model.使用多威布尔模型进行生存外推。
Stat Methods Med Res. 2015 Apr;24(2):287-301. doi: 10.1177/0962280211419645. Epub 2011 Sep 20.
3
Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology.
系统评价将外部证据纳入基于试验的生存外推法用于卫生技术评估的方法。
Med Decis Making. 2023 Jul;43(5):610-620. doi: 10.1177/0272989X231168618. Epub 2023 Apr 26.
4
Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trials in Health Technology Assessment.混合生存曲线:一种从健康技术评估临床试验中推断事件时间结局的新方法。
Med Decis Making. 2023 Apr;43(3):299-310. doi: 10.1177/0272989X221134545. Epub 2022 Oct 31.
5
Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio.利用总体风险比模型评估医疗干预措施降低死亡率的效果时可能存在的偏倚。
Pharmacoeconomics. 2020 Mar;38(3):285-296. doi: 10.1007/s40273-019-00859-5.
6
An Evaluation of Survival Curve Extrapolation Techniques Using Long-Term Observational Cancer Data.利用长期观测性癌症数据评估生存曲线外推技术。
Med Decis Making. 2019 Nov;39(8):926-938. doi: 10.1177/0272989X19875950. Epub 2019 Oct 20.
7
flexsurv: A Platform for Parametric Survival Modeling in R.flexsurv:R语言中用于参数生存建模的一个平台。
J Stat Softw. 2016 May 12;70. doi: 10.18637/jss.v070.i08.
8
Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods.利用外部数据从随机试验推断生存率:方法综述
Med Decis Making. 2017 May;37(4):377-390. doi: 10.1177/0272989X16639900. Epub 2016 Jul 10.
基于大型临床试验对预期寿命的实证估计:左截断、右删失生存分析方法的应用
Stat Med. 2008 Nov 20;27(26):5525-55. doi: 10.1002/sim.3355.
4
Life expectancy as an indicator of outcome in follow-up of population-based cancer registries: the example of childhood leukemia.基于人群的癌症登记随访中预期寿命作为结局指标:以儿童白血病为例。
Ann Oncol. 2006 Jan;17(1):167-71. doi: 10.1093/annonc/mdj050. Epub 2005 Oct 25.
5
Bayesian evidence synthesis to extrapolate survival estimates in cost-effectiveness studies.贝叶斯证据合成法在成本效益研究中推断生存估计值
Stat Med. 2006 Jun 15;25(11):1960-75. doi: 10.1002/sim.2366.
6
Polyhazard models for lifetime data.寿命数据的多风险模型。
Biometrics. 1999 Dec;55(4):1281-5. doi: 10.1111/j.0006-341x.1999.01281.x.
7
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.植入式心脏复律除颤器二级预防试验的荟萃分析。AVID、CASH和CIDS研究。抗心律失常药物与植入式除颤器研究。汉堡心脏骤停研究。加拿大植入式除颤器研究。
Eur Heart J. 2000 Dec;21(24):2071-8. doi: 10.1053/euhj.2000.2476.